Vilazodone: A 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders

CNS Neuroscience and Therapeutics

Volumn 15, Issue 2, 2009, Pages 107-117

  Dawson, Lee A ^a   Watson, Jeannette M ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

5 HT1A; 5 Hydroxytryptamine (5 HT); Anxiety; Autoreceptor; Depression; Serotonin specific reuptake inhibitor (SSRI); Serotonin transporter (SERT)

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; BUSPIRONE; DIAZEPAM; DRUG METABOLITE; FLUOXETINE; MONOAMINE OXIDASE INHIBITOR; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PAROXETINE; PINDOLOL; SEROTONIN 1 RECEPTOR; SEROTONIN 1A AGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VILAZODONE; ZIDOMETACIN; ANTIDEPRESSANT AGENT; BENZOFURAN DERIVATIVE; INDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; SEROTONIN 1A RECEPTOR; SEROTONIN AGONIST; SEROTONIN TRANSPORTER;

ANXIETY DISORDER; BEHAVIOR; CLINICAL EVALUATION; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERANCE; FORCED SWIMMING TEST; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; MAJOR DEPRESSION; MOOD DISORDER; NAUSEA; NEGATIVE FEEDBACK; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NONHUMAN; PARTIAL AGONISM; PREFRONTAL CORTEX; REM SLEEP; REVIEW; SEROTONIN UPTAKE; SEROTONINERGIC SYSTEM; SINGLE DRUG DOSE; SOMNOLENCE; TRANQUILIZING ACTIVITY; VOCALIZATION; ANIMAL; DRUG POTENTIATION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT;

ANIMALS; ANTIDEPRESSIVE AGENTS; BENZOFURANS; HUMANS; INDOLES; MOOD DISORDERS; PIPERAZINES; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN AGONISTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS;

EID: 65549167936     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2008.00067.x     Document Type: Review

References (84)

1. Woolley DW, Shaw E. A biochemical and pharmacological suggestion about certain mental disorders. Proc Natl Aced Sci USA 1954 40 : 228 231.
2. Abi-Dargham A, Laruelle M, Aghajanian GK, Charney D, Krystal J. The role of serotonin in the pathophysiology and treatment of schizophrenia. J Neuropsychiatr Clin Neurosci. 1997 9 : 1 17. (Pubitemid 27075408)
3. Zohar J, Mueller EA, Insel TR, Zohar-Kadouch RC, Murphy DL. Serotonin responsivity in obsessive-compulsive disorder. Arch Gen Psychiatr 1987 44 : 946 951.
4. Zohar J, Zohar-Kadouch RC, Kindler S. Current concepts in the pharmacological treatment of obsessive-compulsive disorder. Drugs 1992 43 : 210 218.
5. Briley M, Chopin P. Serotonin in anxiety: Evidence from animal models. In : Sandler M, Coppen A, Harnett S, editors. 5-Hydroxytryptamine in psychiatry: A spectrum of ideas. Oxford : Oxford University Press. 1991 177 197.
6. Briley M, Chopin P. Is anxiety associated with hyper or pypo- serotonergic state? In : Palomo T., Archer T., editors. Strategies for studying brain disorders, depression, anxiety and drug abuse disorders. Vol. 1, Editorial complutence. Madrid, Spain : Donoso Cortes. 1994 197 209.
7. Goodwin FK, Bunney WE Jr. Depressions following reserpine: A re-evaluation. Semin Psychiatry 1971 3 : 435 448.
8. Coppen A, Shaw DM, Malleson A, Eccleston E, Gundy G. Tryptamine metabolism in depression. Br J Psychiatr 1965 111 : 993 998.
9. Coppen A, Shaw DM, Herzberg B, Maggs R. Tryptophan in the treatment of depression. Lancet 1967 2 : 1178 1180.
10. Shopsin B. Enhancement of the antidepressant response to L-tryptophan by a liver pyrrolase inhibitor: A rational treatment. Neuropsychobiol 1978 4 : 188 192. (Pubitemid 8264576)
11. Delgado JMR, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Physchiatr 1990 47 : 411 418. (Pubitemid 20161259)
12. Cowen PJ. A role for 5-HT in the action of antidepressant drugs. Pharmacol Ther 1990 46 : 43 51. (Pubitemid 20067879)
13. Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of patients with depression treated with serotonin re-uptake inhibitors. Arch Gen Psychiatr 1994 51 : 248 251. (Pubitemid 24081512)
14. Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol. 1995 15 : 217 222.
15. Svensson TH. Attenuated feedback inhibition of brain serotonin synthesis following chronic administration of imipramine. Naunyn-Schmiedeberg's Arch Pharmacol 1978 302 : 115 118. (Pubitemid 8287522)
16. 1A agonist gepirone: Electrophysiological studies in the rat brain. Synapse 1987 1 : 470 480. (Pubitemid 17120914)
17. Blier P, De Montigny C, Chaput Y. Modifications of the serotonin system by antidepressant treatments: Implications for the therapeutic response in major depression. J Clin Psychopharmacol 1987 7 : 24 35. (Pubitemid 18014273)
18. Dawson LA, Nguyen HQ, Smith DL, Schechter LE. Effects of chronic fluoxetine treatment, in the presence and absence (±) pindolol: A microdialysis study. Br J Pharmacol 2000 130 : 797 804. (Pubitemid 30389058)
19. Dawson LA, Nguyen HQ, Smith DL, Schechter LE. Effect of chronic fluoxetine and WAY-100635 treatment on serotonergic neurotransmission in the frontal cortex. J Psychopharmacol 2002 16 : 145 152. (Pubitemid 34614884)
20. 1A autoreceptors by a low chronic fluoxetine dose effect of the concurrent administration of WAY-100635. Neuropsychopharmacol 2001 24 : 11 20.
21. Blier P, Chaput Y, De Montigny C. Long-term 5-HT re-uptake blockade, but not monoamine oxidase inhibition, decreases the function of terminal 5-HT autoreceptors: An electrophysiological study in the rat brain. Naunyn-Schmiedeberg's Arch Pharmacol 1988 337 : 246 254. (Pubitemid 18124919)
22. 1B mRNA in a sequential manner in the rat dorsal raphe nucleus. Neuropsychopharmacol 1996 15 : 515 522. (Pubitemid 26389875)
23. 1 Receptor augmentation strategies as enhanced efficacy therapeutics for psychiatric disorders. Curr Topics Med Chem 2008 8 : 1008 1023.
24. Adell A, Castro E, Celada P, Bortolozzi A, Pazos A, Artigas F. Strategies for producing faster acting antidepressants. Drug Discov Today 2005 10 : 578 585. (Pubitemid 40552825)
25. Artigas F, Adell A, Celada P. Pindolol augmentation of antidepressant response. Curr Drug Targets. 2006 7 : 139 147.
26. 1A receptor antagonist and an SSRI in vivo: Effects on 5-HT cell firing and extracellular 5-HT. Br J Pharmacol 2005 115 : 1064 1070.
27. Lucki I. Behavioural studies of serotonin receptor agonists as antidepressant drugs. J Clin Psychiatr 1991 52 : 24 31.
28. Gould E. Serotonin and hippocampal neurogenesis. Neuropsychopharmacol 1999 21 : 46S 51S. (Pubitemid 29396470)
29. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000 20 : 9104 9110. (Pubitemid 32042912)
30. Schechter LE, Bolanos FJ, Gozlan H, Lanfumey L, Haj-Dahmane S, Laporte AM, Fattaccini CM, Hamon M. Alterations of central serotoninergic and dopaminergic neurotransmission in rats chronically treated with ipsapirone: Biochemical and electrophysiological studies. J Pharmacol Exp Ther 1990 255 : 1335 1347.
31. 2 receptor-mediated behavior by continuous gepirone treatment. Life Sci 1991 49 : 1777 1785.
32. 1A agonists in the treatment of depression? Biol Psychiatr 2003 53 : 193 203. (Pubitemid 36135929)
33. Fitton A, Benfield P. Gepirone in depression and anxiety disorders. CNS Drugs 1994 1 : 388 398.
34. Landon M, Eriksson E, Agren H, Fahlen T. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin re-uptake inhibitors. J Clin Psychopharmacol 1999 19 : 268 273. (Pubitemid 29233022)
35. Michelson D, Bancroft J, Targum S, Kim Y, Tepner R. Female sexual dysfunction associated with antidepressant administration: A randomized, placebo-controlled study of pharmacologic intervention. Am J Psychiatr 2000 157 : 239 243. (Pubitemid 30080904)
36. Fava M. New approaches to the treatment of refractory depression. J Clin Psychiatry. 2000 61 (Suppl 1 26 32. (Pubitemid 30124147)
37. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, Ritz L, Nierenberg AA, Lebowitz BD, Biggs MM, et al. STARD Study Team. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006 354 : 1243 1252. (Pubitemid 44098067)
38. 1A receptor agonists and serotonin reuptake inhibitors. J Med Chem. 2004 47 : 4684 4692. (Pubitemid 39195559)
39. 1A agonists and 5-HT re-uptake inhibitors by combination of indole-butyl-amine and chromenonyl-piperazine structural elements in a single molecular entity. Bioorg Med Chem 2004 12 : 4843 4852. (Pubitemid 39164392)
40. Heinrich T, Böttcher H. A new synthesis of indole 5-carboxylic acids and 6-hydroxy-indole-5-carboxylic acids in the preparation of an o-hydroxylated metabolite of vilazodone. Bioorg Med Chem Lett 2004 14 : 2681 2684. (Pubitemid 38519073)
41. Hewitt NJ, Bühring KU, Dasenbrock J, Haunschild J, Ladstetter B, Utesch D. Studies comparing in vivo:in vitro metabolism of three pharmaceutical compounds in rat, dog, monkey, and human using cryopreserved hepatocytes, microsomes, and collagen gel immobilized hepatocyte cultures. Drug Metab Dispos 2001 29 : 1042 1050. (Pubitemid 32605921)
42. 1A-agonist EMD 68843. Soc Neurosci Abstr 1996 22 : 613.
43. 1A receptor agonistic properties. Eur J Pharmacol 1997 322 : 147 153.
44. 1A receptor agonist-antagonist binding affinity difference as a measure of intrinsic activity in recombinant and native tissue systems. B J Pharmacol. 2000 130 : 1108 1114. (Pubitemid 30453546)
45. Page ME, Cryan JF, Sullivan A, Dalvi A, Saucy B, Manning DR, Lucki, I. Behavioral and neurochemical effects of 5-4-4-(5-cyano-3-indolyl)-butyl)-butyl- 1-piperazinyl-benzofuran-2-carboxamide (EMD 68843): A combined selective inhibitor of serotonin re-uptake and 5-hydroxytryptamine(1A) receptor partial agonist. J Pharmacol Exp Therap 2002 302 : 1220 1227.
46. 1D receptor antagonist in native tissue. B J Pharmacol. 2001 133 : 797 806. (Pubitemid 32751788)
47. 2 receptors. Br J Pharmacol. 1998 125 : 1413 1420. (Pubitemid 28548552)
48. 1A receptor partial agonist/serotonin re-uptake inhibitor, vilazodone. Eur J Pharmacol 2005 510 : 49 57. (Pubitemid 40312389)
49. 1A-mediated inhibition of serotonin synthesis: Possible relationship to anxiolytic properties of 5-hydroxytryptamine agonists. Mol Pharmacol 1990 37 : 231 237. (Pubitemid 20082987)
50. 1A receptors in hippocampal and cortical homogenates. Eur J Pharmacol. 2000 390 : 67 73. (Pubitemid 30122438)
51. 1A receptors negatively coupled to adenylyl cyclase activity in rat hippocampal membranes. Mol Pharmacol 1992 41 : 1066 1072. (Pubitemid 23026106)
52. Roberts C, Hagan JJ, Bartoszyk GD, Kew JNC. Effect of vilazodone on 5-HT efflux and re-uptake in the guinea pig dorsal raphe nucleus. Eur J Pharmacol 2005 517 : 59 63. (Pubitemid 40910253)
53. 11C-labelled 2-(phenylthio)araalkylamines. J Med Chem. 2000 43 : 3103 3110. (Pubitemid 30626767)
54. 11C-DASB: A probe for in vivo measurements of the serotonin transporter by positron emission tomography. Nucl Med Biol. 2002 29 : 509 515. (Pubitemid 34667112)
55. 2 receptors: Microdialysis studies in the awake and anaesthetized rat. Neuropharmacol 1994 33 : 411 421. (Pubitemid 124015963)
56. Chen NH, Reith MEA. Monoamine interactions measured by microdialysis in the ventral tegmental area of rats treated systemically with (+/-)-8-hydroxy-2-(di-n-propylamino) tetralin. J Neurochem 1995 64 : 1585 1597.
57. Suzuki M, Matsuda T, Asano S, Somboonthum P, Takuma K, Baba A. Increase of noradrenaline release in the hypothalamus of freely moving rat by postsynaptic 5-hydroxytryptamine(1A) receptor activation. Br J Pharmacol 1995 115 : 703 711.
58. 1A receptor activation. Br J Pharmacol 1992 106 : 603. (Pubitemid 23002937)
59. 1A receptors in a series of N4-substituted arylpiperazines. J Med Chem 1995 38 : 4044.
60. 1A receptor activation in vivo. Life Sci 1995 56 : PL 163.
61. 1A receptor agonist 8-OH-DPAT on the release of 5-HT in dorsal and median raphe-innervated rat brain regions as measured by in vivo microdialysis. Life Sci 1991 48 : 1779 1786.
62. Pellow P, Chopin S, File E, Briley M. Validation of open: Closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Method 1985 14 : 149 167. (Pubitemid 16239568)
63. Treit D. A comparison of anxiolytic and nonanxiolytic agents in the shock-probe burying test for anxiolytics. Pharmacol Biochem Behav 1990 36 : 203 205. (Pubitemid 20165661)
64. Treit D, Menard J, Royan C. Anxiogenic stimuli in the elevated plus-maze. Pharmacol Biochem Behav 1993 44 : 463 469. (Pubitemid 23040601)
65. Treit D, Degroot A, Kashluba S, Bartoszyk GD. Systemic EMD 68843 injections reduce anxiety in the shock-probe, but not the plus-maze test. Eur J Pharmacol 2001 414 : 245 248.
66. Adamec R, Bartoszyk GD, Burton P. Effects of systemic injections of vilazodone, a selective serotonin re-uptake inhibitor and serotonin 1A receptor agonist, on anxiety induced by predator stress in rats. Eur J Pharmacol. 2004 504 : 65 77. (Pubitemid 39410725)
67. Porsolt RD, Bertin A, Jalfre M. Behavioural despair in mice: A primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977a 229 : 327 336. (Pubitemid 8225714)
68. Porsolt RD, Le Pichon M, Jalfre M. Depression: A new animal model sensitive to antidepressant treatments. Nature 1977b 266 : 730 732. (Pubitemid 8073804)
69. Borsini F, Meli A. Is the forced swimming test a suitable model for revealing antidepressant activity. Psychopharmacol 1988 94 : 147 160. (Pubitemid 18040687)
70. Cesana R, Ceci A, Ciprandi C, Borsini F. Mesulergine antagonism towards the fluoxetine anti-immobility effects in the forced swimming test in mice. J Pharm Pharmacol 1993 45 : 473 475. (Pubitemid 23162449)
71. Bourin M, Hascoet M, Colombel M-C, Redrobe JP, Baker GB. Differential effects of clonidine, lithium, and quinine in the forced swimming test in mice for antidepressants: Possible roles of serotonergic systems. Eur Neuropsychopharmacol, 1996 6 : 231 236. (Pubitemid 26281562)
72. 1B receptors in antidepressant drug actions in the mouse forced swimming test. Eur J Pharmacol 1996 318 : 213 220. (Pubitemid 27046261)
73. Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol 1997 8 : 523 532. (Pubitemid 27504702)
74. Sanchez, C., Meier, E. Behavioural profiles of SSRIs in animal models of depression, anxiety and aggression - are they all alike? Psychopharmacol 1997 129 : 197 205. (Pubitemid 27085389)
75. 1A receptors. Neuropharmacol 1993 32 : 331 342. (Pubitemid 23122632)
76. 1B receptor mutant mice. J Pharmacol Exp Ther 2001 298 : 1101 1107.
77. 1A receptor antagonist WAY100635. Br J Pharmacol 2000 130 : 1713 1719. (Pubitemid 30611953)
78. 1B receptor antagonists. Pharmacol Biochem Behav. 2004 77 : 69 75. (Pubitemid 38076982)
79. Dawson LA, Nguyen HQ. Effects of 5-HTIA receptor antagonists on fluoxetine-induced changes in extracellular serotonin concentrations in rat frontal cortex. Eur J Pharmacol. 1998 345 : 41 46. (Pubitemid 28179468)
80. 1A receptor agonist. Neuropsychopharmacol 2003 28 : 445 456.
81. 1A agonist EMD 68843. Psychopharmacol 2001 155 : 167 192.
82. Rabiner EA, Gunn RN, Wilkins MR, Sargent PA, Mocaer E, Sedman E, Cowen PJ, Grasby PM. Drug action at the 5-HT(1A) receptor in vivo: Autoreceptor and postsynaptic receptor occupancy examined with PET and carbonyl-(11)CWAY-100635. Nucl Med Biol 2000 27 : 509 513. (Pubitemid 30658155)
83. 1A receptor agonist radioligand O-methyl- 11C2-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3, 5(2H,4H)dione in non-human primates. Eur J Nucl Med Mol Imaging 2007 34 : 1050 1060. (Pubitemid 46919551)
84. 1B autoreceptor antagonist and 5-HT re-uptake inhibitor in native tissue. Eur J Pharmacol. 2006 536 : 54 61.